ALX Oncology Holdings (ALXO) EBITDA Yield: History & Chart

ALX Oncology Holdings Inc.(ALXO)

Biotechnology · South San Francisco, CA

$1.16-0.05 (-4.55%)

Delayed quote: Oct 6, 2026, 11:35 AM EDT

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

South San Francisco, CA

48 employees

www.alxoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jason Lettmann

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
ALX Oncology Holdings Inc. (ALXO)	$155.42M	N/A	N/A	N/A	N/A
Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›	$155.86M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$154.46M	N/A	N/A	N/A	N/A
Inogen, Inc. (INGN)vs ›	$157.30M	N/A	4.75%	3.30%	2.87%
Minerva Neurosciences, Inc. (NERV)vs ›	$157.44M	N/A	38.61%	38.61%	38.61%
Anavex Life Sciences Corp. (AVXL)vs ›	$152.63M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$151.93M	N/A	1.29%	1.28%	1.28%
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$150.96M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$147.97M	N/A	0.81%	0.81%	0.81%
PepGen Inc. (PEPG)vs ›	$163.12M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

ALX Oncology Holdings Inc. (ALXO)

$155.42M

N/A

Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›

$155.86M

N/A

Cardiol Therapeutics Inc. (CRDL)vs ›

$154.46M

N/A

Inogen, Inc. (INGN)vs ›

$157.30M

N/A

4.75%

3.30%

2.87%

Minerva Neurosciences, Inc. (NERV)vs ›

$157.44M

N/A

38.61%

Anavex Life Sciences Corp. (AVXL)vs ›

$152.63M

N/A

Codexis, Inc. (CDXS)vs ›

$151.93M

N/A

1.29%

1.28%

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$150.96M

N/A

LifeMD, Inc. (LFMDP)vs ›

$147.97M

N/A

0.81%

PepGen Inc. (PEPG)vs ›

$163.12M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

ALXO EBITDA Yield Metrics

ALXO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics